证券代码：600222 证券简称：太龙药业 公告编号：临 2025-025 被担保人名称：河南太龙药业股份有限公司（以下简称"公司" 或"上市公司"）。 担保人：桐君堂药业有限公司（以下简称"桐君堂"），系公 司全资子公司。 本次担保金额及已实际为其提供的担保余额：全资子公司桐君 堂为公司在中国光大银行股份有限公司郑州如意西路支行（以下简称 "光大银行郑州如意西路支行"）最高额不超过人民币 12,000 万元 的授信提供连带责任保证；截至本公告披露日，桐君堂已实际为公司 提供的担保余额为 12,000 万元(含本次)。 一、担保情况概述 （一）基本情况 为满足公司日常经营发展资金需求，近日公司全资子公司桐君堂 与光大银行郑州如意西路支行签订《最高额保证合同》，为公司在光 大银行郑州如意西路支行申请的期限为 18 个月的最高额不超过人民 本次担保是否有反担保：否 对外担保逾期的累计数量：无 河南太龙药业股份有限公司 关于子公司为上市公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：60 ...

Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

证券代码：600222 证券简称：太龙药业 公告编号：2025-024 河南太龙药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 4 月 29 日 (二)股东大会召开的地点：郑州高新技术产业开发区金梭路 8 号公司一楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 227 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 154,915,976 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 28.0176 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长尹辉先生主持，以现场投票和网络 投票相结合的方式进行表决。本次股东大会的召集、召开及表决方式符合《公 ...

河南仟问律师事务所关于河南太龙药业股份有限公司 2024 年年度股东大会的法律意见书 河南仟问律师事务所 HENAN CHAIN-WIN LAW FIRM 郑州市郑东新区平安大道189号正商环湖国际12F 电话（Tel）: 0371-65953550 传真(Fax): 0371-65953502 网址：http://www.shineway.org.cn 电子邮件：E-mail:qwlss@126.com 仟见字[2025]第 131 号 关于河南太龙药业股份有限公司 2024 年年度股东大会的法律意见书 致：河南太龙药业股份有限公司 河南仟问律师事务所（以下简称"本所"）接受河南太龙药业股份有限公司（以 下简称"公司"）的委托，委派本所律师出席公司 2024 年年度股东大会（以下简 称"本次股东大会"），就本次股东大会的召集和召开程序，出席本次股东大会人 员的资格，审议事项及其表决程序等相关事宜出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件、 材料。公司保证其向本所提供的文件和材料是完整、真实和有效的，且一切足以 影响本法律意见书的事实、文件和材料均已向本所披露，无任何隐 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥323,274,192.26, a decrease of 35.23% compared to ¥499,111,557.06 in the same period last year[3] - Net profit attributable to shareholders was ¥1,530,570.06, down 92.80% from ¥21,258,639.34 year-on-year[3] - The company reported a basic earnings per share of ¥0.0028, a decline of 92.65% from ¥0.0381 in the same period last year[3] - The company reported a net profit of CNY 2,631,142.99 for Q1 2025, down 87.3% from CNY 20,521,428.43 in Q1 2024[17] - The total comprehensive income attributable to the parent company owners was CNY -5,065,852.08, compared to CNY 12,579,812.36 in the previous period, indicating a significant drop[18] Cash Flow - The net cash flow from operating activities improved significantly to ¥10,950,449.57, compared to a negative cash flow of ¥115,823,793.88 in the previous year, marking a 109.45% change[3] - Cash received from sales of goods and services was CNY 414,804,628.03, down from CNY 479,171,900.81, reflecting a decrease of approximately 13.5%[22] - The net cash flow from investing activities was CNY 89,445,610.07, compared to CNY 100,273,498.41 in the previous period, showing a decline of about 10.8%[23] - Cash inflow from financing activities was CNY 424,609,780.95, an increase from CNY 266,303,164.84, representing a growth of approximately 59.4%[23] - The ending cash and cash equivalents balance was CNY 367,798,047.03, up from CNY 213,271,783.83, indicating an increase of about 72.5%[23] - The total operating cash outflow was CNY 406,284,927.59, compared to CNY 596,965,172.27 in the previous period, indicating a reduction of about 32%[22] Assets and Liabilities - The total assets at the end of the reporting period increased by 2.17% to ¥3,565,530,775.02 from ¥3,489,768,020.93 at the end of the previous year[4] - Cash and cash equivalents increased to CNY 403,944,947.01 as of March 31, 2025, compared to CNY 180,039,805.83 at the end of 2024[12] - The company’s total liabilities increased to CNY 1,934,505,598.17 from CNY 1,863,525,871.55 at the end of 2024[14] - The long-term investments increased to CNY 205,932,079.69 as of March 31, 2025, compared to CNY 197,722,648.31 at the end of 2024[12] - The company’s inventory stood at CNY 364,819,936.82, slightly down from CNY 367,673,786.87 at the end of 2024[12] Segment Performance - The gross margin in the traditional Chinese medicine segment improved slightly despite a decrease in revenue due to market conditions[9] - The company is focusing on high-value customers in the Chinese medicine decoction pieces segment, resulting in a revenue decline but an increase in gross margin[9] - The pharmaceutical research and development service segment faced increased market competition, leading to a decrease in revenue, although project gross margins improved through cost control measures[9] - Gross profit margin for the pharmaceutical formulation segment was 48.69%, a decrease of 2.41% year-over-year[10] - Revenue from traditional Chinese medicine pieces was CNY 180,761,496.70, with a year-over-year decline of 21.57%[10] Return on Investment - The weighted average return on net assets decreased to 0.10%, down from 1.34% in the previous year[3] - The basic and diluted earnings per share were CNY 0.0028, down from CNY 0.0381 in the previous period, reflecting a decrease of approximately 92.6%[18] Sales and Marketing - The company has integrated its existing sales channels, which has impacted product sales during the transition period[9]

[Table_Main] 公司研究|医疗保健|制药、生物科技与生命科学 证券研究报告 太龙药业(600222)公司研究报告 2025 年 04 月 25 日 [Table_Title]大股东持续赋能，多业务齐头并进 ——太龙药业（600222.SH）首次覆盖报告 [Table_Summary] 报告要点： 河南省医药头部企业，大股东持续赋能，业绩稳健增长 太龙药业 1993 年建厂，1999 年在上海证券交易所上市，是河南省医药行 业首家上市公司。2015 年，公司全资收购桐君堂和北京新领先，进军中药 饮片和医药研发外包业务，形成了目前药品制剂、中药饮片和药品研发服务 三大核心业务板块。公司大股东是郑州泰容产业投资有限公司，持有公司 14.37%的股份，公司实控人是郑州高新技术产业开发区管委会。高新产投 是河南省内国有投资机构，未来将持续推进公司在中医药、CXO 和大健康 等领域的战略发展与实施，在资金、资源和产业整合方面为公司赋能增量。 双黄连口服液引领发展，中药饮片有望厚积薄发 公司中药口服液核心品种是双黄连口服液，2024 年底双黄连口服液（儿童 型）参加全国中成药采购联盟集中采购并成功中选，进一步推动 ...

Investment Rating - The report gives a "Buy" rating for Tai Long Pharmaceutical [4] Core Views - Tai Long Pharmaceutical is a leading pharmaceutical company in Henan Province, with steady growth in performance driven by its major shareholder's continuous support and the development of multiple business segments [1][20] - The company's core business segments include pharmaceutical formulations, traditional Chinese medicine (TCM) pieces, and pharmaceutical research and development services, which are expected to contribute to future growth [1][20][22] Summary by Sections Company Overview - Established in 1993 and listed in 1999, Tai Long Pharmaceutical is the first listed company in Henan's pharmaceutical industry. The company has expanded its business through acquisitions, including Tong Jun Tang and Beijing Xin Ling, to enter the TCM and pharmaceutical R&D outsourcing sectors [1][14][16] Business Segments - The main product in the TCM oral liquid segment is Shuanghuanglian Oral Liquid, which is expected to maintain steady growth due to successful procurement and market expansion efforts [2][42] - The TCM pieces business, primarily operated by Tong Jun Tang, is projected to benefit from national procurement initiatives, leading to rapid growth [43][50] - The pharmaceutical R&D outsourcing sector, led by Beijing Xin Ling, is anticipated to recover as the industry stabilizes, with expected revenue growth in the coming years [3][64] Financial Forecast - Revenue projections for 2025-2027 are estimated at CNY 2.13 billion, CNY 2.32 billion, and CNY 2.53 billion, respectively, with net profits of CNY 66 million, CNY 98 million, and CNY 117 million [4][72] - The earnings per share (EPS) are forecasted to be CNY 0.11, CNY 0.17, and CNY 0.20 for the same period, with corresponding price-to-earnings (P/E) ratios of 45x, 30x, and 25x [4][72] Market Position - The company has a strong market position in the pediatric medication segment, with a product cluster that includes various oral liquids for children, enhancing its competitive edge [2][42] - The TCM oral liquid market is projected to grow, supported by increasing demand for respiratory system treatments, with the market size reaching CNY 75.88 billion in 2023 [36][39] Research and Development - R&D investment has increased significantly, from CNY 56.92 million in 2021 to CNY 108.78 million in 2024, indicating a commitment to innovation and product development [51][53] - The company has a robust pipeline of products under development, including traditional Chinese medicine formulations and high-end generic drugs, which are expected to drive long-term growth [53][55]

河南太龙药业股份有限公司 2024 年年度股东大会会议资料 2025 年 4 月 | 2024 年年度股东大会会议须知 . | | --- | | 2024 年年度股东大会会议议程 . | | 议案一 2024 年年度报告及其摘要 . | | 议案二 2024 年度董事会工作报告 . | | 议案三 2024 年度监事会工作报告 . | | 议案四 2024 年度财务决算报告 | | 议案五 关于 2024 年度利润分配方案的议案 | | 议案六 关于公司 2025 年度向银行等金融机构申请综合授信额度的 | | 议案 . | | 议案七 关于 2025 年度预计为下属全资及控股子公司提供担保的议 | | 家 ………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 31 | | 议案八 关于续聘会计师事务所的议案 …………………………………………………………………………………………………………………………………………38 | 2024 年年度股东大会会议须知 ...

中药饮片方面，全资子公司桐君堂药业致力于安全、有效、道地的中药饮片生产销售。报告期内，在保 障浙江省内优质客户续标率的同时，主动参与周边省份招标工作，成功入围省外多家公立医院的招采名 单；在全国中药饮片采购联盟集中采购中，成功中标36个品种，63个品规，中标区域覆盖河南、山东、 福建、江苏、上海等多个省市，为中药饮片业务后续在全国市场的销售奠定基础。 药品研发服务方面，控股子公司北京新领先专注为客户提供综合性医药技术研发服务。报告期内，合同 签订量同比增长11%，受托和自主立项的研发项目中，新增58项注册申报、32项药品生产批件、17项药 品通过一致性评价、5项原料药通过审评获批。 对于2025年经营计划，太龙药业表示，公司聚焦中药制造与药品研发服务业务，做强药品制剂、做优中 药饮片、做精研发服务、拓展"中药+"大健康产业链，加强战略性资源投入，提高业务协同聚合力，保 持中药业务稳步增长，持续精进CXO研发服务实力；充分运用投融资策略，发挥资本驱动力，积极寻 找适宜的投资项目和标的，储备公司发展资源；持续提升公司治理水平，锻造可持续发展新质动能。 中证报中证网讯(王珞)4月8日晚，太龙药业（600222）公布 ...

桐君堂先后在浙江、河北、内蒙古等地新增专业化种植公司，不断丰富原材料的品种及种、养殖规模， 坚持药材质量保障，完善中药材全过程追溯体系建设；在中药材价格持续波动的市场环境下，通过地域 调研、种源鉴定、共建共享基地、供应商沟通会，实施多次集中招采等措施合理控制供应链成本，新增 数家优势供应商，达成多个品种成本下降。 同时深化生产流程规范管理，完善内控与质量标准，巩固各项降本增效举措，创新发酵技术，加快煎药 中心智能化升级，提升"云煎药"服务响应效率，在保障浙江省内优质客户续标率的同时，主动参与周边 省份招标工作，成功入围省外多家公立医院的招采名单；并精准把握中药饮片集采政策和市场优质优价 导向，在全国中药饮片采购联盟集中采购中，成功中标 36 个品种，63 个品规，中标区域覆盖河南、山 东、福建、江苏、上海等多个省市，为中药饮片业务后续在全国市场的销售奠定基础。 种植基地建设和药材流通业务方面，公告披露，公司在河南、山东、浙江、甘肃、山西、内蒙古等道地 药材产区以自建和"公司+合作社+农户"共建等形式，建立了连翘、金银花、黄芩、柴胡、丹参、太子 参、白术、栀子、当归、黄芪等 70 余个规范化中药材种（养）植基地 ...